back

Selected Publication :

1. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I.  Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Katano H, Takahashi H, Matsuda J, Sata T, Kurata T, Nagashima K, Hall WW.  Nat Med. 2006 Apr;12(4):466-472. 

2. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C(12)U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.   Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Chiba J, Sata T, Kurata T, Hasegawa H. Microbes Infect. 2007 Sep;9(11):1333-40. 

3. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.   Hasegawa H, Ichinohe T, Tamura S, Kurata T.

Expert Rev Vaccines. 2007 Apr;6(2):193-201.

4. Inhibition of the SDF-1α-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.  Kawaguchi A, Orba Y, Kimura T, Iha H, Ogata M, Tsuji T, Ainai A, Sata T, Okamoto T, Hall W.W, Sawa H, Hasegawa H. Blood 2009 Oct 1;114(14):2961-8. 

5. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.  Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. Ther Clin Risk Manag. 2009 Feb;5(1):125-32.

6. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.  El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y, Nicot C, Hermine O, Hall W, de Thé H, Bazarbachi A.  J Exp Med. 2010 Dec 20;207(13):2785-92. 

7. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.   van Riet E, Ainai A, Suzuki T, Hasegawa H.　Vaccine 2012 Aug 31;30(40):5893-900.